Tirzepatide vs Retatrutide: Research Peptide Comparison
Share
Tirzepatide vs Retatrutide: how the two research peptides compare
Tirzepatide and Retatrutide are the two most requested metabolic research peptides in Australia. They are related but not the same: the key difference is how many receptors each one targets. This comparison breaks down the mechanisms, the research context, handling, and how to choose between them for a study. Both are available from Australian stock at Bondi Labs: Tirzepatide and Retatrutide.
Supplied strictly for laboratory research use only. Not for human or veterinary use.
The core difference in one line
Tirzepatide is a dual receptor agonist (GLP-1 and GIP). Retatrutide is a triple receptor agonist (GLP-1, GIP and glucagon). Retatrutide adds glucagon receptor activity on top of the two pathways Tirzepatide already targets.
Side-by-side comparison
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptor targets | GLP-1 + GIP (dual) | GLP-1 + GIP + glucagon (triple) |
| Research generation | Established dual agonist | Next-generation triple agonist |
| Studied endpoints | Glucose regulation, appetite signalling | Glucose regulation, appetite signalling, energy expenditure |
| Form | Lyophilised powder | Lyophilised powder |
| Purity | 99%+ HPLC, COA per batch | 99%+ HPLC, COA per batch |
How each one works in research
GLP-1 and GIP receptor activity is associated in the literature with glucose handling and appetite signalling. Tirzepatide combines those two into a single molecule, which is why it became a benchmark dual-agonist reference compound. Retatrutide keeps both of those and adds glucagon receptor activity, which is linked in research to energy expenditure. The added third pathway is the reason Retatrutide is studied as a distinct, more comprehensive metabolic model rather than simply a stronger version of Tirzepatide.
Which should you choose for a study?
It depends on the pathways your protocol is designed around. If the research question is about dual GLP-1/GIP signalling, Tirzepatide is the direct reference. If the question involves glucagon-receptor contribution or a triple-agonist model, Retatrutide is the compound built for it. Many labs keep both on hand to compare dual versus triple mechanisms directly. For deeper background on the triple agonist, see the Retatrutide research guide.
Handling and reconstitution
Both peptides ship as lyophilised powder and are reconstituted with bacteriostatic water before use. Add the water slowly against the vial wall, do not shake, and store the solution refrigerated at 2 to 8°C away from freeze-thaw cycles. Use the reconstitution calculator to set your concentration, or follow the step-by-step Retatrutide reconstitution guide.
Buying in Australia
Bondi Labs supplies both compounds from Australian stock with same-day dispatch before 12pm AEST, a COA per batch, and tracked delivery nationwide. Shop Tirzepatide or Retatrutide, or browse the full research peptide range.
Frequently asked questions
Is Retatrutide stronger than Tirzepatide?
They are not measured that way. Retatrutide targets one additional receptor (glucagon), so it models a different, broader mechanism rather than being a "stronger" version of the same thing.
Can Tirzepatide and Retatrutide be compared in the same study?
Yes, comparing a dual agonist against a triple agonist is a common research design, which is why labs often stock both.
Are both available in Australia?
Yes, both are held in Australian stock at Bondi Labs with same-day dispatch before 12pm AEST.
Disclaimer: Supplied strictly for laboratory research use only. Nothing here is medical advice or a therapeutic claim, and none of these statements has been evaluated by the TGA or FDA. Not for human or veterinary use.